PharmiWeb.com - Global Pharma News & Resources
16-Jan-2019

Global Bispecific Antibody Market: Drug Sales & Clinical Pipeline Insight, 2025 - ResearchAndMarkets.com

The "Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025" report has been added to ResearchAndMarkets.com's offering.

Report Highlights

  • Applications of Bispecific Antibodies
  • Global Bispecific Antibody Market Overview: Drug & Market Sales
  • Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
  • US & Japan Market Share Opportunity: >40% by 2025
  • Bispecific Antibody Clinical Pipeline: 224 Drugs
  • Commercially Available Bispecific Antibody: 2 (HEMLIBRA & Blincyto)

As per report findings, the market opportunity of bispecific antibodies is estimated to surpass US$ 8 Billion by 2025 driven by application of existing commercially available bispecific antibodies to other multiple indications and increasing regulatory approvals from developing and developed markets.

Currently, there are 2 bispecific antibodies (HEMLIBRA and Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.

The market for bispecific antibodies is quiet bright as they are the new emerging trends in the market. BsAbs due their specificity are gaining a lot of interest from multiple stake holders from the pharmaceutical industry.

The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

Currently, there are more than 200 bispecific antibodies in the clinical trials and this number is further expected to increase in coming years driven by research and development and the favorable commercial success to 2 bispecific antibodies available in the market.

The future for the research and development of bispecific antibodies remains highly progressive and profitable option driven by the fact that increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stake holders of the industry.

Topics Covered

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism of Action of Bispecific Antibody

4. The Design & Engineering of IgG like Bispecific Antibodies

5. The Design & Engineering of Small Bispecific Antibodies

6. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

7. Applications of Bispecific Antibodies

8. Global Bispecific Antibody Market Overview

9. Global Bispecific Antibody Market Dynamics

10. Global Bispecific Antibody Market Future Prospects

11. Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

12. Marketed Global Bispecific Antibodies Clinical Insight by Company & Indication

13. No Development Reported & Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

14. Competitive Landscape

  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • NovImmune
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/rlf7sz/global_bispecific?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005543/en/

Editor Details

Last Updated: 16-Jan-2019